Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia

Bagán, Leticia; Sáez, Guillermo T.; Tormos, Maria C.; Labaig-Rueda, Carlos; Murillo-Cortés, Judith; Bagán, José

doi:10.1007/s00784-015-1551-z

Cited by 18 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fourteen studies included controls and compared their results with either normal oral mucosa, conventional oral leukoplakia, reactive lesions, or malignant tumors . Ten studies only analyzed biomarker expression (whether the biomarkers were present or not/strength of staining) .…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies only analyzed biomarker expression (whether the biomarkers were present or not/strength of staining) . Four studies analyzed how biomarker expression was association with clinical and/or histological data . Three studies correlated the biomarkers expression with progression and/or malignant transformation .…”

Section: Resultsmentioning

confidence: 99%

“…Because heterogeneity was an issue, Gouvêa et al was excluded from further analysis. Five of the patient series were described from Spain . Bagan et al could possibly have overlapping patients, but because meta‐analysis was not done for EBV, this did not pose a problem in this review.…”

Section: Discussionmentioning

confidence: 99%

“…The sample size was often small, 10 studies included 10 or less PVL patients . Only five studies included 20 or more PVL patient cases . McShane et al presented reporting recommendations for tumor marker prognostic studies to encourage transparent and complete reporting and to allow the adequate assessment of the quality of the study and the generalizability of the results.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Proliferative verrucous leukoplakia and its tumor markers: Systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

Background The aim was to update information on oral proliferative verrucous leukoplakia (PVL), a disease of verrucous‐like lesions with high risk of malignancy, and its biomarkers. Methods A systematic search of literature on PVL and its biomarkers showed 22 biomarkers that were investigated in 19 papers. A meta‐analysis was possible for human papillomavirus (HPV), aneuploidy, Ki‐67, and p53. Results Aneuploidy was found consistently (I2 = 0%, P = 0.61) in 92% (95% CI 80%‐99%) of the PVL cases. P53 positivity prevalence was 27% (95% CI 15%‐40%) in two available studies (I2 = 0%, P = 0.64). With HPV and Ki‐67, the most outlying studies needed to be removed and after that the pooled HPV positivity prevalence (I2 = 24%, P = 0.27) was 5% (95% CI 0%‐14%) and for Ki‐67 (I2 = 9%, P = 0.33) 14% (95% CI 6%‐26%). Conclusions With the evidence of the current literature, aneuploidy could value as a biomarker of PVL but should be further validated.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Proliferative verrucous leukoplakia and its tumor markers: Systematic review and meta‐analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated valuable associations among OSCC clinical stages and prognosis, and salivary or serum markers associated with TAM’s dynamic participation in the tumour stroma [58, 68, 70–73]. Although salivary markers associated to TAM polarization are not yet used as parameters for definitive diagnoses, they should be taken into consideration to evaluate patients with potent malignant disorders, like proliferative verrucous leukoplakia [74], as well as for recurrence in OSCC treated patients.…”

Section: Introductionmentioning

confidence: 99%

Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge

et al. 2017

View full text Add to dashboard Cite

BackgroundOral squamous cell carcinoma (OSCC) accounts over 90% of malignant neoplasms of the oral cavity. This pathological entity is associated to a high mortality rate that has remained unchanged over the past decades. Tumour-associated macrophages (TAMs) are believed to have potential involvement in OSCC progression. However, the molecular networks involved in communication between stroma and cancer cells have not yet been fully elucidated.Main bodyThe role of M2 polarized cells in oral carcinogenesis is supported by a correlation between TAMs accumulation into OSCC stroma and poor clinical outcome. Signalling pathways such as the NF-κB and cytokines released in the tumour microenvironment promote a bidirectional cross-talk between M2 and OSCC cells. These interactions consequently result in an increased proliferation of malignant cells and enhances aggressiveness, thus reducing patients’ survival time.ConclusionsHere, we present a comprehensive review of the role of interleukin (IL)-1, IL-4, IL-6, IL-8, IL-10 and the receptor tyrosine kinase Axl in macrophage polarization to an M2 phenotype and OSCC progression. Understanding the molecular basis of oral carcinogenesis and metastatic spread of OSCC would promote the development of targeted treatment contributing to a more favourable prognosis.

show abstract

Potential noninvasive biomarkers for the malignant transformation of oral leukoplakia: A systematic review and meta‐analysis

et al. 2023

View full text Add to dashboard Cite

Background:The rising cancer incidence in patients with oral leukoplakia (OL) highlights the importance of identifying potential biomarkers for high-risk individuals and lesions because these biomarkers are useful in developing personalized management strategies for OL patients.This study systematically searched and analyzed the literature on potential saliva and serum biomarkers for OL malignant transformation.Methods: PubMed and Scopus were searched for studies published up to April 2022. The primary outcome of this study was the difference in biomarker concentrations in saliva or serum samples from healthy control (HC), OL and oral cancer (OC) populations. Cohen's d with 95% credible interval was calculated and pooled using the inverse variance heterogeneity method.Results: A total of seven saliva biomarkers were analyzed in this paper, including interleukin-1alpha, interleukin-6 (IL-6), interleukin-6-8, tumor necrosis factor alpha (TNF-α), copper, zinc, and lactate dehydrogenase. IL-6 and TNF-α exhibited statistically significant deviations in comparisons between HC versus OL and OL versus OC. A total of 13 serum biomarkers were analyzed, including IL-6, TNF-α, C-reactive protein, total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins, albumin, protein, β2-microglobulin, fucose, lipid-bound sialic acid (LSA), and total sialic acid (TSA). LSA and TSA exhibited statistically significant deviations in comparisons between HC versus OL and OL versus OC. Conclusion:IL-6 and TNF-α in saliva have strong predictive values for OL deterioration, and LSA and TSA concentration levels in serum also have the potential to serve as biomarkers for OL deterioration.

show abstract

Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia

Abstract: Salivary and plasma IL-6 are altered in patients with PVL, with more extensive verrucous areas being associated to the highest IL-6 levels. This could be a significant tool for monitoring patients with PVL, their progression to more advances stages and their recurrences.

Cited by 18 publications

References 50 publications

Proliferative verrucous leukoplakia and its tumor markers: Systematic review and meta‐analysis

Proliferative verrucous leukoplakia and its tumor markers: Systematic review and meta‐analysis

Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge

Potential noninvasive biomarkers for the malignant transformation of oral leukoplakia: A systematic review and meta‐analysis

Contact Info

Product

Resources

About